Chart Industries GTLS Biomedical — Restructuring Costs
Discontinued — last reported Q4 '17
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Chart Industries in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCosts.
The official record: Chart Industries’s 10-K, filed February 22, 2018, on SEC EDGAR. View the filing →
Questions, answered.
- What does biomedical — restructuring costs mean?
- The total accounting cost of reorganizing or downsizing the Biomedical segment.
- How do you interpret biomedical — restructuring costs?
- High costs indicate significant organizational change, which may be necessary for long-term efficiency but impacts short-term profitability.
- How does biomedical — restructuring costs compare across companies?
- Comparable to 'Restructuring Charges' reported by companies undergoing organizational realignment.